Haemonetics Corporation’s HAE share price has dipped by 11.58%, which has investors questioning if this is right time to buy.

Learn more about whether Haemonetics Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue ...

While reporting financial results for the third quarter on Thursday, healthcare company Haemonetics Corp. (HAE) narrowed its adjusted ...

Based on the one-year price targets offered by 10 analysts, the average target price for Haemonetics Corp (NYSE:HAE) is $110.80 with a high estimate of $125.00 and a low estimate of $85.00.

Net Leverage Ratio: Approximately 2.42 times EBITDA. Haemonetics Corp (NYSE:HAE) reported a 4% increase in third-quarter revenue on a reported basis, with adjusted earnings per share up 14%.

Q3 2025 Earnings Call Transcript February 6, 2025 Operator: Good day, and welcome to the Haemonetics Third Quarter Fiscal ...

Haemonetics Corporation (NYSE:HAE) stock dropped about 12% after the blood supplies company missed Q3 revenue estimates, despite posting a 3.7% year-over-year increase. Quarterly revenue came in ...

Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ETCompany ParticipantsOlga Guyette - Vice President, ...

Analysts expect Haemonetics to post earnings of $1.20 per share and revenue of $354.46 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so ...